Digipath Labs, Next Stop Colorado

DigiPath, Inc. (DIGP) announced today that its affiliate, DigiPath Labs Colorado LLC, has been granted a conditional state license to operate a cannabis testing facility in Denver, Colorado. In accordance with Colorado licensing requirements, Dr. Cindy Orser, a Colorado resident, is the sole owner of DigiPath Labs Colorado. Dr. Orser serves as the Chief Science Officer of DigiPath Labs Inc., and is a cannabis-testing expert who frequently speaks on the importance of quality assurance, the dangers of pesticide contamination, and the need for standard testing protocols. DigiPath Labs Colorado intends to license the standard operating procedures developed and validated for cannabis testing by DigiPath Labs, Inc. in Las Vegas, Nevada.


DigiPath Labs logo

“Obtaining a conditional license is the first step in the licensing requirements required for the opening of a cannabis testing lab in the State of Colorado.  DigiPath Labs Colorado plans to bring reliable, replicable quality assurance and potency testing to the Colorado cannabis market, which will benefit Colorado’s cannabis industry—from the producer to the dispensary owner to the state — from a business liability and consumer and patient safety standpoint,” says Dr. Orser.

“Contaminants in cannabis can aggravate or even cause patient health problems, such as liver disease,” says Dr. Orser. “The addition of microbial screening to retail marijuana testing has been a positive step by Colorado to come into line with standardization in cannabis testing.” Colorado has yet to make quality assurance testing of medical marijuana products mandatory, but the state is planning to commence a comprehensive medical marijuana testing program in 2016.

“Knowing that pesticide-contaminated products exist in their marketplace, both medical marijuana patients and recreational cannabis users want quality assurance that their cannabis products are safe,” explains Dr. Orser.

The absence of uniform testing rules to determine potency, homogeneity, and contaminants creates inconsistent and unreliable test results and reporting, according to an article in the Denver Post. Potency and contamination levels can vary widely between different labs.

Dr. Orser is routinely called upon to deliver expert testimony on cannabis testing, which helps lawmakers and law enforcement understand the importance of cannabis testing and adopting rigorous standards. Dr. Orser recently spoke about the importance of standards in cannabis testing at the Emerald Conference.

“Standards are seamlessly integrated into our lives—and for very good reasons,” said Dr. Orser. “When you take a 350 mg aspirin, you can be confident it won’t contain 500 mg or might not contain any aspirin at all. You don’t have to worry it might contain mercury, pesticides or mold. We need that kind of reliability in marijuana products.”

About DigiPath

DigiPath, Inc. supports the cannabis industry’s best practices for reliable testing and brings unbiased cannabis news coverage to the nation. DigiPath’s two business units are DigiPath Labs and TNM News Corp. DigiPath Labs Colorado LLC will license DigiPath Labs’ successfully validated protocols. DigiPath Labs is a wholly owned subsidiary of DigiPath, Inc.

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include information relating to future events, and future financial and operating performance.  Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, and other information that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact: DigiPath Labs, Inc.

Logo –

Show More

Richard Lowe

Richard Lowe is a 14-year veteran of the financial sector with licenses as a commodity broker (Series 3) and investment advisor representative (IAR Series 65). Along with a focus on raising capital for the firms he was employed with, he also wrote and edited much of the content published by them. He holds a BA in Journalism from the University of Massachusetts. He has been a longtime advocate for marijuana legalization due to the social injustices associated with marijuana prohibition and the strong potential for the medicinal benefits of cannabis.

Related Articles

Leave a Reply

Back to top button